These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 21871283)

  • 21. The impact of aprotinin on blood loss and blood transfusion in off-pump coronary artery bypass grafting.
    Bittner HB; Lemke J; Lange M; Rastan A; Mohr FW
    Ann Thorac Surg; 2008 May; 85(5):1662-8. PubMed ID: 18442562
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A propensity score case-control comparison of aprotinin and tranexamic acid in high-transfusion-risk cardiac surgery.
    Karkouti K; Beattie WS; Dattilo KM; McCluskey SA; Ghannam M; Hamdy A; Wijeysundera DN; Fedorko L; Yau TM
    Transfusion; 2006 Mar; 46(3):327-38. PubMed ID: 16533273
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High-dose aprotinin, blood product transfusions, and short-term outcome in neonates and infants: a pediatric cardiac surgery center experience.
    Bojan M; Boulat C; Peperstraete H; Pouard P
    Paediatr Anaesth; 2012 Aug; 22(8):818-25. PubMed ID: 22416677
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differential effects of aprotinin and tranexamic acid on outcomes and cytokine profiles in neonates undergoing cardiac surgery.
    Graham EM; Atz AM; Gillis J; Desantis SM; Haney AL; Deardorff RL; Uber WE; Reeves ST; McGowan FX; Bradley SM; Spinale FG
    J Thorac Cardiovasc Surg; 2012 May; 143(5):1069-76. PubMed ID: 22075061
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bleeding in cardiac surgery: the use of aprotinin does not affect survival.
    Pagano D; Howell NJ; Freemantle N; Cunningham D; Bonser RS; Graham TR; Mascaro J; Rooney SJ; Wilson IC; Cramb R; Keogh BE
    J Thorac Cardiovasc Surg; 2008 Mar; 135(3):495-502. PubMed ID: 18329459
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of tranexamic acid vs. aprotinin on blood loss and transfusion requirements after cardiopulmonary bypass: a prospective, randomised, double-blind trial.
    Hekmat K; Zimmermann T; Kampe S; Kasper SM; Weber HJ; Geissler HJ; Mehlhorn U
    Curr Med Res Opin; 2004 Jan; 20(1):121-6. PubMed ID: 14741082
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Risks and predictors of blood transfusion in pediatric patients undergoing open heart operations.
    Székely A; Cserép Z; Sápi E; Breuer T; Nagy CA; Vargha P; Hartyánszky I; Szatmári A; Treszl A
    Ann Thorac Surg; 2009 Jan; 87(1):187-97. PubMed ID: 19101294
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A comparison of aprotinin and lysine analogues in high-risk cardiac surgery.
    Fergusson DA; Hébert PC; Mazer CD; Fremes S; MacAdams C; Murkin JM; Teoh K; Duke PC; Arellano R; Blajchman MA; Bussières JS; Côté D; Karski J; Martineau R; Robblee JA; Rodger M; Wells G; Clinch J; Pretorius R;
    N Engl J Med; 2008 May; 358(22):2319-31. PubMed ID: 18480196
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The risks associated with aprotinin use: a retrospective study of cardiac cases in Nova Scotia.
    Riddell RE; Buth KJ; Sullivan JA
    Can J Anaesth; 2013 Jan; 60(1):16-23. PubMed ID: 23132043
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of aprotinin on short-term and long-term outcomes after coronary artery bypass grafting surgery.
    Wang X; Zheng Z; Ao H; Zhang S; Wang Y; Zhang H; Hu S
    Ann Thorac Surg; 2010 May; 89(5):1489-95. PubMed ID: 20417766
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Variability of plasma aprotinin concentrations in pediatric patients undergoing cardiac surgery.
    Oliver WC; Fass DN; Nuttall GA; Dearani JA; Schrader LM; Schroeder DR; Ereth MH; Puga FJ
    J Thorac Cardiovasc Surg; 2004 Jun; 127(6):1670-7. PubMed ID: 15173722
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of blood-sparing efficacy of ε-aminocaproic acid and tranexamic acid in newborns undergoing cardiac surgery.
    Martin K; Gertler R; Sterner A; MacGuill M; Schreiber C; Hörer J; Vogt M; Tassani P; Wiesner G
    Thorac Cardiovasc Surg; 2011 Aug; 59(5):276-80. PubMed ID: 21425054
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The risk-benefit profile of aprotinin versus tranexamic acid in cardiac surgery.
    Karkouti K; Wijeysundera DN; Yau TM; McCluskey SA; Tait G; Beattie WS
    Anesth Analg; 2010 Jan; 110(1):21-9. PubMed ID: 19910626
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Use of aprotinin in cardiac surgery: effectiveness and safety in a population-based study.
    Jakobsen CJ; Søndergaard F; Hjortdal VE; Johnsen SP
    Eur J Cardiothorac Surg; 2009 Nov; 36(5):863-8. PubMed ID: 19782573
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Aprotinin is not associated with postoperative renal impairment after primary coronary surgery.
    Lindvall G; Sartipy U; Ivert T; van der Linden J
    Ann Thorac Surg; 2008 Jul; 86(1):13-9. PubMed ID: 18573391
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Low dose aprotinin and low dose tranexamic acid in elective cardiac surgery with cardiopulmonary bypass.
    Waldow T; Krutzsch D; Wils M; Plötze K; Matschke K
    Clin Hemorheol Microcirc; 2009; 42(4):269-77. PubMed ID: 19628892
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role of endogenous kallikrein inhibition in perioperative transfusion and adverse outcome in cardiac surgical patients.
    O'Malley CM; Frumento RJ; Mackie IJ; Gallimore MJ; Hirsh AL; Bennett-Guerrero E
    J Cardiothorac Vasc Anesth; 2007 Feb; 21(1):23-7. PubMed ID: 17289475
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Meta-analysis comparing the effectiveness and adverse outcomes of antifibrinolytic agents in cardiac surgery.
    Brown JR; Birkmeyer NJ; O'Connor GT
    Circulation; 2007 Jun; 115(22):2801-13. PubMed ID: 17533182
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Aprotinin's effect on blood product transfusion in off-pump bilateral lung transplantation.
    Balsara KR; Morozowich ST; Lin SS; Davis RD; Phillips-Bute BG; Hartwig M; Appel JZ; Welsby IJ
    Interact Cardiovasc Thorac Surg; 2009 Jan; 8(1):45-8. PubMed ID: 18669527
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Morbidity and mortality risk factors in adults with congenital heart disease undergoing cardiac reoperations.
    Giamberti A; Chessa M; Abella R; Butera G; Carlucci C; Nuri H; Frigiola A; Ranucci M
    Ann Thorac Surg; 2009 Oct; 88(4):1284-9. PubMed ID: 19766822
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.